Evidence map›Paper›PMID 41286322›Full record

ArticleScientific reports2025

PER3 suppresses lung adenocarcinomatous cell proliferation/migration through activating AMPK/mTOR pathway.

Guanli Yuan, Yinfeng Liu, Dawei Wu, Jingping Xu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Guanli Yuan *Department of General Practice, the First Hospital of Qinhuangdao, Qinhuangdao, 050000, Hebei, China.
Yinfeng Liu *Department of Breast Disease Center, the First Hospital of Qinhuangdao, Qinhuangdao, 050000, Hebei, China.
Dawei WuDepartment of Oncology and Hematology, Qinhuangdao Integrated Traditional Chinese and Western Medicine Hospital of Hebei Port Group Co., Ltd, Qinhuangdao City, 050000, Hebei, China.
Jingping XuDepartment of General Practice, the First Hospital of Qinhuangdao, Qinhuangdao, 050000, Hebei, China. JingpingXu_Qin@126.com.

Funding

Qinhuangdao S&T Plan Program 202401A109
6 · The paper itself

Abstract

Dysregulation of circadian rhythm genes is related to the increased risk of development of various human cancers. This study investigated the biological roles of Period circadian regulator 3 (PER3) in the development and progression of lung adenocarcinoma and related underlying mechanisms. The expression of PER3 was decreased in lung adenocarcinoma and its low expression was correlated with advanced disease stages. Lentiviral-transduced overexpression of PER3 inhibited but PER3 silencing promoted proliferation, migration and invasion of lung adenocarcinomatous cells, suggesting that it played an anti-carcinogenic role in the development and progression of lung adenocarcinoma. Mechanistically, PER3 overexpression elevated the phosphorylation level of AMPK and reduced the phosphorylation level of mTOR, but PER3 silencing produced the opposite effects. More importantly, the inhibitory effects of PER3 overexpression on cellular proliferation, migration and invasion were partially reversed by the AMPK/mTOR pathway inhibitor. Correspondingly, the promoting effects of PER3 silencing on proliferation, migration and invasion was partially reversed by the AMPK/mTOR pathway activator. These findings collectively suggest that PER3 regulated biological behaviors of lung adenocarcinomatous cells through activating the AMPK/mTOR pathway. PER3 may be a promising biomarker and therapeutic target for lung adenocarcinoma.

Indexed as

Adenocarcinoma of LungAMP-Activated Protein KinasesCell MovementLung NeoplasmsPeriod Circadian ProteinsSignal TransductionTOR Serine-Threonine KinasesCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPhosphorylationAMP-Activated Protein KinasesMTOR protein, humanPeriod Circadian ProteinsTOR Serine-Threonine KinasesAMPK/mTOR pathwayLung adenocarcinomaPeriod circadian regulator 3 (PER3)

Identifiers

PMID41286322
PMCPMC12644904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.